Over the last several decades, the animal health market has outgrown the U.S. economy and been more resistant to economic cycles. Moreover, the vet market is an attractive vehicle for investors to participate in the growth of the broader healthcare industry without reimbursement risk. U.S. consumers will spend an estimated $55.53 billion on pets this year - a number that has been growing at a pace of more than 5% over the past decade. Therapeutics constitutes a small portion of this market but is poised to expand as pet care becomes more complex and companies roll out new products for unmet needs. In this article, we decided to evaluate Aratana Therapeutics (PETX), a small-cap biopharmaceutical company developing...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|